Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 3

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 3
---
 transactions. See the section entitled “Plan of Distribution” for more information. We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the selling stockholders or their donees, pledgees, assignees, transferees or other successors-in-interest,except with respect to amounts received by us upon exercise of the Pre-FundedWarrants, the Series A Common Stock Warrants and the Series B Common Stock Warrants (collectively, the “Warrants”), to the extent the Warrants are exercised for cash. We will bear the out-of-pocketcosts, expenses, and fees incurred in connection with the registration of the shares of common stock to be sold by the selling stockholders pursuant to this prospectus. Other than registration-related expenses, the selling stockholders will bear their own broker or similar commissions payable with respect to any sales of their shares of common stock and any legal fees or other costs of the selling stockholders related thereto. Our common stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the trading symbol “PSTV.” On April 3, 2025, the closing sale price of our common stock was $0.77 per share. Investing in our shares of common stock involves a high degree of risk that are described in the section entitled “ Risk Factors ” beginning on page 3 of this prospectus and under similar headings in the documents incorporated by reference into this prospectus. You should also review carefully any risk factors included in any applicable prospectus supplement for a discussion of additional risks that you should consider before investing in our common stock. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is , 2025.

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                |     |  ii |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |     | iii |
| PROSPECTUS SUMMARY                                   |     |   1 |
| OUR COMPANY                                          |     |   1 |
| THE OFFERING                                         |     |   2 |
| RISK FACTORS                                         |     |   3 |
| USE OF PROCEEDS                                      |     |   4 |
| SELLING STOCKHOLDERS                                 |     |   6 |
| PLAN OF DISTRIBUTION                                 |